Benitec Biopharma targets mid-2027 start for BB-301 pivotal trial in OPMD dysphagia

By Public Technologies
  • Benitec outlined an FDA regulatory update for BB-301, keeping its pivotal OPMD study on track to start enrollment in mid-2027.
  • FDA discussions continue on an open-label, single-arm pivotal design; the agency requested additional data, including the company’s OPMD natural history study.
  • Final pivotal study design is expected to be confirmed in 1Q 2027, subject to FDA review of the added information.
  • Interim Phase 1b/2a results have not yet been presented; they will be shown as a late-breaking poster at ESGCT on Oct. 27-30, 2026.
  • The update signals continued regulatory alignment, supporting the planned transition from early-stage testing into a pivotal program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839296) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.